Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa

AIDS Research and Human Retroviruses

Volumn 28, Issue 4, 2012, Pages 324-332

  Green, Taryn N ^a   Archary, Mohendran ^a   Gordon, Michelle L ^a   Padayachi, Nagavelli ^a   Lie, Yolanda ^b   Anton, Elizabeth D ^b   Reeves, Jacqueline D ^b   Grobler, Anneke ^c   Bobat, Raziya ^a   Coovadia, Hoosen ^a   Ndung'U, Thumbi ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b MONOGRAM BIOSCIENCES   (United States)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

AFRICA; AGE DISTRIBUTION; ARTICLE; CD4+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; DRUG CHOICE; DRUG MONITORING; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE PHENOTYPE CORRELATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SALVAGE THERAPY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; THYMIDINE ANALOGUE MUTATION; TREATMENT FAILURE; VIRAL TROPISM; VIROLOGICAL FAILURE; VIRUS DETECTION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS; PHYLOGENY; PREDICTIVE VALUE OF TESTS; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, HIV; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; TREATMENT FAILURE; TRIAZOLES;

EID: 84859208553     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0106     Document Type: Article

References (40)

1. UNAIDS: Report on the global AIDS epidemic. Available at http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/ 2008-Global-report.asp. Accessed July 1, 2009.
2. Hamers RL, Derdelinckx I, van Vugt M, Stevens W, Rinke de Wit TF, and Schuurman R: The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther 2008;13:625-639.
3. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al.: Maraviroc (UK-427,857), a potent, orally bioavail-able, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49:4721-4732.
4. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, et al.: A new classification for HIV-1. Nature 1998; 391:240.
5. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-628.
6. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, et al.: In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997;3:1259-1265.
7. Choge I, Cilliers T, Walker P, Taylor N, Phoswa M, Meyers T, et al.: Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res Hum Retroviruses 2006;22:458-465.
8. Ndung'u T, Sepako E, McLane MF, Chand F, Bedi K, Gaseitsiwe S, et al.: HIV-1 subtype C in vitro growth and cor-eceptor utilization. Virology 2006;347:247-260.
9. Connell BJ, Michler K, Capovilla A, Venter WD, Stevens WS, and Papathanasopoulos MA: Emergence of X4 usage among HIV-1 subtype C: Evidence for an evolving epidemic in South Africa. AIDS 2008;22:896-899.
10. Johnston ER, Zijenah LS, Mutetwa S, Kantor R, Kitti-nunvorakoon C, and Katzenstein DA: High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol 2003;77: 7682-7688.
11. Raymond S, Delobel P, Mavigner M, Ferradini L, Cazabat M, Souyris C, et al.: Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. J Acquir Immune Defic Syndr 2010;53:167-175.
12. DOH: Guidelines for the management of HIV-infected children. Available at http://www.doh.gov.za/docs/factsheets/guidelines/hiv/part5.pdf. Accessed December 8, 2008.
13. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, et al.: Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007;51:566-575.
14. Trinh L, Han D, Huang W, Wrin T, Larson J, Kiss L, et al.: Technical validation of an enhanced sensitivity Trofile HIV co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5. Antiviral Ther 2008; 13:A128.
15. Reeves JD, Coakley E, Petropoulos CJ, and Whitcomb JM: An enhanced-sensitivity Trofile™ HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: A review of analytical and clinical studies. J Viral Entry 2009;3:94-102.
16. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, et al.: Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008; 82:3952-3970.
17. Singh A, Page T, Moore PL, Allgaier RL, Hiramen K, Coovadia HM, et al.: Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates. Virology 2009;393:56-67.
18. Coetzer M, Cilliers T, Ping LH, Swanstrom R, and Morris L: Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology 2006;356:95-105.
19. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F, et al.: Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66:3183-3187.
20. Jensen MA, Coetzer M, van 't Wout AB, Morris L, and Mullins JI: A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol 2006;80:4698-4704.
21. Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK, Domingues FS, et al.: Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 2007;12: 1097-1106.
22. Tamura K, Dudley J, Nei M, and Kumar S: MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007;24:1596-1599.
23. Guindon S and Gascuel O: A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 2003;52:696-704.
24. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, et al.: Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999;73:152-160.
25. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al.: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009;4:e4724.
26. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al.: Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009;17:138-145.
27. Soares EA, Santos AF, Gonzalez LM, Lalonde MS, Tebit DM, Tanuri A, et al.: Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage. J Antimicrob Chemother 2009;64: 938-944.
28. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al.: Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008;359:2233-2244.
29. Davies MA, Wood R, Van CutsemG, Giddy J, Eley B, Rabie H, et al.: Virologic failure and second-line antiretroviral therapy (ART) in children in South Africa: The international epidemi-ologic databases to evaluate AIDS (leDEA) Southern Africa collaboration. 5th IAS Conference on Pathogenesis, Treatment and Prevention. Cape Town, 2009.
30. Hosseinipour MC, van Oosterhout JJ, Weigel R, Phiri S, Kamwendo D, Parkin N, et al.: The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009;23:1127-1134.
31. Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Apeagyei K, Hampton J, et al.: Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008;46:1589-1597.
32. Wallis CL, Erasmus L, Varughese S, Ndiweni D, and Stevens WS: Emergence of drug resistance in HIV-1 subtype C infected children failing the South African national anti-retroviral roll-out program. Pediatr Infect Dis J 2009;28:1123-1125.
33. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynho-ven B, Cane P, et al.: Impact of HIV-1 subtype and anti-retroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med 2005;2:e112.
34. Wallis CL, Mellors JW, Venter WD, Sanne I, and Stevens W: Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010;53:480-484.
35. Joly V, Descamps D, Peytavin G, Touati F, Mentre F, Duval X, et al.: Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs. Antimicrob Agents Chemother 2004;48:172-175.
36. Martinson NA, Morris L, Gray G, Moodley D, Pillay V, Cohen S, et al.: Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2007;44:148-153.
37. Briz V, Poveda E, del Mar Gonzalez M, Martin-Carbonero L, Gonzalez-Gonzalez R, and Soriano V: Impact of anti-retroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years. J Antimicrob Chemother 2008;61:405-410.
38. Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, et al.: Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006;194:926-930.
39. Garrido C, Roulet V, Chueca N, Poveda E, Aguilera A, Skrabal K, et al.: Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol 2008;46: 887-891.
40. Low AJ, Dong W, Chan D, Sing T, Swanstrom R, Jensen M, et al.: Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 2007;21:F17-24.